Odyssey Health, Inc.

Equities

ODYY

US67612C1027

Market Closed - OTC Markets Other stock markets 14:38:15 2024-06-07 EDT			5-day change	1st Jan Change
0.0299 ^USD	+6.60%		-15.77%	-70.10%

03-22	Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI
2023	Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	CI

ODYSSEY HEALTH, INC. : Other Events (form 8-K)

November 23, 2022 at 05:18 pm

Item 8.01 Other Material Event

On November 18, 2022, Odyssey Health, Inc. (the "Company"), received its research and development rebate from the government of Australia. The rebate in the amount of $313,709 ($468,727 AUD), is for clinical work performed in Australia related to our Phase I human clinical trial during the Company's fiscal year ending July 31, 2022.

Latest news about Odyssey Health, Inc.

Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	03-22	CI
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	12-27	CI
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	12-15	CI
Odyssey Health, Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	23-10-30	CI
Odyssey Health, Inc. Announces the Resignation of John Gandolfo as Director	23-10-06	CI
Oragenics, Inc. entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	23-10-04	CI
Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS	23-08-23	CI
Odyssey Health, Inc. executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.	23-06-27	CI
Odyssey Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-14	CI
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-17	CI
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-17	CI
Odyssey Health, Inc. Appoints Jeffrey Conroy as Director	23-01-13	CI
Odyssey Health, Inc. to Develop Intranasal Field- Deliverable Nerve Agent Antidote	23-01-12	CI
Odyssey Health, Inc. Announces Resignation of Jeffrey Conroy as Director	23-01-06	CI
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022	22-12-14	CI
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development	22-11-23	CI
Odyssey Health Inc. Announces Expansion of Executive Team	22-11-03	CI
Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device	22-11-01	CI
Odyssey Health, Inc. Reports Earnings Results for the Full Year Ended July 31, 2022	22-10-31	CI
Odyssey Health, Inc. Auditor Raises 'Going Concern' Doubt	22-10-30	CI
Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases	22-10-11	CI
Odyssey Health, Inc. Decides to Dissolve its Sports Advisory Board	22-10-03	CI
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug	22-09-28	CI
Odyssey Health, Inc. Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II	22-09-13	CI
Odyssey Health, Inc. Announces the Successful Completion of Safety Measures for Their Phase I Multi-Day Ascending Dosing Clinical Trial	22-08-18	CI

Chart Odyssey Health, Inc.

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data